A handful of small, early-stage clinical trials are investigating whether CAR-T therapy can improve symptoms in multiple ...

Multiple sclerosis (MS) is a chronic, often debilitating autoimmune disease that affects the central nervous system (CNS). This disease causes the immune system to mistakenly attack the protective ...

Briumvi significantly outperformed Aubagio at reducing disease activity in people with highly active relapsing forms of MS, a ...

Applegate recalled the less obvious signs she ignored for years.

In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a 70.8% relative reduction ...

Chen, M.Y. and Luo, L.P. (2026) CT and MRI Findings of Epithelioid Hemangioma of Bone: A Case Report. Journal of Biosciences and Medicines, 14, 246-252. doi: 10.4236/jbm.2026.143018 .

An estimated 2.8 million people live with MS worldwide, with prevalence increasing globally. Women make up about 75 percent ...

Patients with a particular histopathologic phenotype may respond less well to rituximab, but it is still unclear what factors ...

"This partnership with Siemens Healthineers marks a pivotal step in expanding access to advanced neuroimaging on a global scale," said Kyle Frye, CEO of Cortechs.ai. "By combining our innovative AI ...

Paramagnetic rim lesions may help assess MS risk in people with radiologically isolated syndrome before symptoms appear.

Participants received either oral fenebrutinib twice daily or oral teriflunomide once daily for at least 96 weeks.

Everclear frontman Art Alexakis shares how a new treatment for multiple sclerosis has helped him hit the road for the band's 30th anniversary tour.